Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ryan R. Kawalerski"'
Autor:
Luke A. Torre-Healy, Ryan R. Kawalerski, Ki Oh, Lucie Chrastecka, Xianlu L. Peng, Andrew J. Aguirre, Naim U. Rashid, Jen Jen Yeh, Richard A. Moffitt
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-10 (2023)
pdacR is an open-source R package and web-based platform that enables community exploration of pancreatic ductal adenocarcinoma (PDAC) gene expression datasets. pdacR is used to interrogate the specificities of popular PDAC molecular subtypes.
Externí odkaz:
https://doaj.org/article/f01dcb81e2df4174b75f2a337239323f
Autor:
Chun‐Hao Pan, Yuka Otsuka, BanuPriya Sridharan, Melissa Woo, Cindy V. Leiton, Sruthi Babu, Mariana Torrente Gonçalves, Ryan R. Kawalerski, Ji Dong K. Bai, David K. Chang, Andrew V. Biankin, Louis Scampavia, Timothy Spicer, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer
Publikováno v:
Molecular Oncology, Vol 14, Iss 8, Pp 1800-1816 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer‐related deaths in the United States by 2020, due in part to innate resistance to widely used chemotherapeutic agents and limited knowledge about key m
Externí odkaz:
https://doaj.org/article/bf1022a47d6a4b55a9aa9bed91852ba0
Autor:
Ryan R. Kawalerski, Mariana Torrente Gonçalves, Chun-Hao Pan, Robert Tseng, Lucia Roa-Peña, Cindy V. Leiton, Luke A. Torre-Healy, Taryn Boyle, Sumedha Chowdhury, Natasha T. Snider, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos
Keratin 17 (K17), an oncofetal intermediate filament protein, is one of the most abundantly expressed proteins in pancreatic ductal adenocarcinomas (PDACs) of the most aggressive molecular subtype. The mechanistic roles of this protein in malignancy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcd6aacf53feda75660210be9a217c9b
https://doi.org/10.1101/2022.08.27.504988
https://doi.org/10.1101/2022.08.27.504988
Publikováno v:
Oncotarget
Pancreatic ductal adenocarcinoma (PDAC), the most common histological subtype of pancreatic cancer, has one of the highest case fatality rates of all known solid malignancies. Over the past decade, several landmark studies have established mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc4d31e2e1b519c062fa59f643e3e70b
https://doi.org/10.18632/oncotarget.27901
https://doi.org/10.18632/oncotarget.27901
Autor:
Hong Jin Kim, Roheena Z. Panni, Silvia Gabriela Herrera, Brian A. Belt, Sarah G. Hennessey, Ashley B. Morrison, Chong Jin, Benjamin Schmidt, Jen Jen Yeh, Naim U. Rashid, Keith E. Volmar, David C. Linehan, Richard A. Moffitt, Audrey E. Chang, Timothy M. Nywening, Ryan R. Kawalerski, KJ Moore, Xianlu L. Peng, Apoorve Nayyar
Publikováno v:
Clin Cancer Res
Purpose: Molecular subtyping for pancreatic cancer has made substantial progress in recent years, facilitating the optimization of existing therapeutic approaches to improve clinical outcomes in pancreatic cancer. With advances in treatment combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4494d85a7bed4723fff77c0d10d07d
https://pubmed.ncbi.nlm.nih.gov/31754050
https://pubmed.ncbi.nlm.nih.gov/31754050
Autor:
Taryn Boyle, Lucia Roa-Peña, Cindy V. Leiton, Natasha T. Snider, Luisa F. Escobar-Hoyos, Ryan R. Kawalerski, Kenneth R. Shroyer
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aebba02705e82d091ff14ce7d5fd0f5
https://doi.org/10.1096/fasebj.2019.33.1_supplement.lb335
https://doi.org/10.1096/fasebj.2019.33.1_supplement.lb335
Autor:
Chun-Hao Pan, Louis Scampavia, Melissa Woo, Sruthi Babu, Kenneth R. Shroyer, Cindy V. Leiton, Pankaj K. Singh, Mariana Torrente Gonçalves, Timothy P. Spicer, Ji Dong K. Bai, Timothy Q. Duong, Luisa F. Escobar-Hoyos, Ryan R. Kawalerski, David K. Chang, Andrew V. Biankin, Yuka Otsuka, Richard A. Moffitt, BanuPriya Sridharan, Jiang Zhao
Publikováno v:
Cancer Research. 80:PO-023
Pancreatic ductal adenocarcinoma (PDAC) includes two molecular subtypes, of which the basal-like subtype is associated with the shortest survival and is highly resistant to chemotherapy. The basal-like subtype is defined by a 25-gene signature; howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7f6915380946be8b5ba501797f9de99
https://doi.org/10.1158/1538-7445.panca20-po-023
https://doi.org/10.1158/1538-7445.panca20-po-023
Autor:
Natasha T. Snider, Mariana Torrente Gonçalves, Lucia Roa-Peña, Kenneth R. Shroyer, Taryn Boyle, Chun-Hao Pan, Luisa F. Escobar-Hoyos, Ryan R. Kawalerski, Luke A. Torre-Healy, Cindy V. Leiton
Publikováno v:
Cancer Research. 80:PO-050
CLINICAL NEED & OBJECTIVES: There is an unmet need for the discovery and development of novel therapeutic approaches for PDAC. Molecular subtyping, however, has recently uncovered potential biomarkers that, subject to further investigation, may be dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cca5fe0bbec9b8f894247471db89979a
https://doi.org/10.1158/1538-7445.panca20-po-050
https://doi.org/10.1158/1538-7445.panca20-po-050
Autor:
Lucia Roa-Peña, Natasha T. Snider, Luke A. Torre-Healy, Cindy V. Leiton, Taryn Boyle, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos, Ryan R. Kawalerski
Publikováno v:
Cancer Research. 79:C26-C26
Clinical Need and Objectives: Our previous reports suggest that keratin 17 (K17), an intermediate filament (IF), is an oncoprotein and biomarker of the most aggressive and treatment-resistant form of pancreatic ductal adenocarcinoma (PDAC). Important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::333957aa99f636e23e8cfd2740538c71
https://doi.org/10.1158/1538-7445.panca19-c26
https://doi.org/10.1158/1538-7445.panca19-c26
Autor:
Sruthi Babu, Chun-Hao Pan, Lucia Roa-Peña, Luisa F. Escobar-Hoyos, Ryan R. Kawalerski, Cindy V. Leiton, Kenneth R. Shroyer
Publikováno v:
Cancer Research. 79:B50-B50
Our aims are to uncover the molecular mechanisms through which keratin 17 (K17), a prognostic biomarker, drives tumor aggression and to target these mechanisms to provide more effective treatment for pancreatic ductal adenocarcinoma (PDAC). In murine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c9942367487a60b44a390cd1f931c31
https://doi.org/10.1158/1538-7445.panca19-b50
https://doi.org/10.1158/1538-7445.panca19-b50